Pharmdca (@Pharmdca) header
Pharmdca (@Pharmdca) profile picture

USC Pharmacy Alumni 💊 | Full-Time Investor 📈 My posts reflect my personal investment views, not investment recommendations. Always do your own due diligence.

United States
Joined September 2013
Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)Photo by Pharmdca (@Pharmdca)
You weren't Warren Buffett 2.0 on the way up. You are not an idiot today. We are both somewhere firmly in between. And as long as we're acting responsibly, that's entirely fine. We will be fine. There will be brighter days. Great companies will not get cheaper forever.
6
2
81
7,560
SANDISK $SNDK 8-FOR-1 STOCK SPLIT IS NOW EFFECTIVE
25
51
13
925
123,047
TRUMP WILL DELIVER A KEYNOTE ADDRESS ON THE IRAN WAR NEXT MONTH: THE NEW YORK POST
24
13
10
196
47,684
Pharmdca retweeted
$RVMD Lifesci PT $338 $RVMD: status quo maintained within pan-RAS space; headline figures include 60.7% ORR, 11.1 months mDOR, 12.8 months mPFS, and 76.6% landmark OS at 12 months in N=61 frontline PDAC patients with 18.3 months median follow-up (see also Prior AACR 2026 Data). We'd also flag an 8.2% rate of CR, as well as a 95% CI for mPFS ranging from 10.8-18.4 months. Competitor $ERAS reads out a larger N but nonetheless early (and somewhat uninterpretable) dataset that clears a minor overhang for $RVMD
$RVMD TRUIST BUY PT$261 Near term,expect investors to focus on tomorrow’s ERAS-0015 believe the principal debate will center on response depth, particularly in KRAS G12D PDAC. Expectations for ERAS-0015 appear to call for ~40-50% overall ORR and potentially 50%+ in G12D, in our investor discussions, which would compare favorably with Rasonque monotherapy’s 30% overall ORR and 24% ORR in G12D. That said, we believe ORR alone is unlikely to resolve the competitive debate. Rasonque has already demonstrated statistically significant OS benefit across RAS subtypes in a randomized ph.III study, including a 0.49 OS HR in G12D, while becoming increasingly entrenched in 2L+ PDAC. In our view, ERAS-0015 and other competitors would ultimately need durable survival data and likely a head-to-head study against Rasonque to fully establish clinically meaningful superiority. Bottom line: focus remains on Rasonque launch execution and its expansion into 1L PDAC
5
9
4,009
Pharmdca retweeted
$RVMD TRUIST BUY PT$261 Near term,expect investors to focus on tomorrow’s ERAS-0015 believe the principal debate will center on response depth, particularly in KRAS G12D PDAC. Expectations for ERAS-0015 appear to call for ~40-50% overall ORR and potentially 50%+ in G12D, in our investor discussions, which would compare favorably with Rasonque monotherapy’s 30% overall ORR and 24% ORR in G12D. That said, we believe ORR alone is unlikely to resolve the competitive debate. Rasonque has already demonstrated statistically significant OS benefit across RAS subtypes in a randomized ph.III study, including a 0.49 OS HR in G12D, while becoming increasingly entrenched in 2L+ PDAC. In our view, ERAS-0015 and other competitors would ultimately need durable survival data and likely a head-to-head study against Rasonque to fully establish clinically meaningful superiority. Bottom line: focus remains on Rasonque launch execution and its expansion into 1L PDAC
$RVMD - Bottomline duration going to be much better then most revenue models had. 👍 high numbers will only go higher $RVMD seems good value here with one of best launches many will see in there lifetime ?
1
4
1
15
8,046
BREAKING: Senate passes Trump-backed bill to speed up permits for power plants, power lines, and data centers in a 62-33 vote.
92
764
119
8,898
479,941
Pharmdca retweeted
$RVMD Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026 •With additional patients and longer follow-up, the combination of RASONQUE plus gemcitabine and nab-paclitaxel demonstrated deep and durable responses in the first-line treatment setting •Results support the ongoing Phase 3 RASolute 303 trial in patients with treatment-naïve metastatic pancreatic cancer
2
7
2
34
8,356
$META PLANS $300 MUSE CHARM WITH FREE VERIZON 5G, TARGETS 10M WEARABLE DEVICE SALES IN H2 2026 Meta plans to price its pocket-sized Muse Charm AI device at $300, with up to 12 months of free Verizon 5G service to access its Muse AI assistant. The company has delayed its smartwatch launch to 2027 to prioritize Charm, using technology originally developed for the watch. Meta has also set an internal target of selling 10 million wearable devices in the second half of 2026 and reaching nearly 7 million monthly active wearable users by year-end. For context, EssilorLuxottica reported selling more than 7 million pairs of Ray-Ban Meta smart glasses in 2025. Sorce: The Information
36
19
14
327
59,314
Pharmdca retweeted
🚨 BREAKING: MARK ZUCKERBERG FIRES BACK AT NVIDIA OVER JENSEN HUANG'S DEPARTURE, QUESTIONS THE COMPANY'S DECISION TO LET GO OF ONE OF THE MOST IMPORTANT LEADERS IN THE TECHNOLOGY INDUSTRY! 🗣️ Mark Zuckerberg stated: "Look, I think what Jensen Huang has built at Nvidia is extraordinary. You don't simply walk away from decades of leadership, innovation and experience and expect everything to continue as if nothing happened. Jensen wasn't just running a company; he was building an ecosystem. His relationships, technical knowledge and ability to bring talented people together played a massive role in making Nvidia what it is today. I understand that companies have standards and boards have difficult decisions to make. But leadership is also about recognising the value someone brings beyond the numbers on a financial report. You can find another CEO, but finding someone who understands the business, the people and the vision at the same level is an entirely different challenge. I believe Nvidia should carefully reconsider what it stands to lose. Sometimes, the biggest mistake a company can make is failing to recognise the value of the person who helped build its success." Nvidia's decision has sparked serious debate across Silicon Valley, with prominent technology figures questioning whether the company can truly replace Huang's influence.
🚨 BREAKING: ELON MUSK SLAMS NVIDIA OVER JENSEN HUANG'S DEPARTURE, COMPARES THE DECISION TO THE CHICAGO BULLS DUMPING MICHAEL JORDAN AND SAYS THE COMPANY MAY HAVE MADE A MASSIVE MISTAKE! Elon Musk has strongly criticised Nvidia over its reported decision to force Jensen Huang out, arguing that losing a leader of his calibre could be a disastrous move for the company. 🗣️ Musk said: "I DON'T THINK HE'S DISLOYAL TO THE UNITED STATES." "Let's say you're the Chicago Bulls. You're on a winning streak, and then you kick Michael Jordan off your team. DOESN'T seem like a smart decision to me!" Musk believes Jensen is virtually irreplaceable, pointing to his exceptional leadership, deep understanding of technology, supply-chain expertise and decades-long industry relationships. He also highlighted the loyalty Jensen commands within Nvidia, saying several members of his team have rejected more lucrative offers elsewhere because they want to continue working with him. President Trump also expressed that it would be great to see Jensen return to Nvidia. Musk added that hiring Jensen would be an honour for him, although he doesn't believe the former Nvidia leader is currently looking for another job. NVIDIA MAY HAVE JUST MADE A HUGE MISTAKE!
76
432
26
3,036
210,001
$AMD SAYS HUNTERBROOK CLAIMS MISREPRESENT AMD'S PRACTICES
22
45
4
695
62,946
Pharmdca retweeted
$RVMD LIFESCI $RVMD (OUTPERFORM,$338.00 PT): EC Grants Marketing Authorization of Rasonque in All European Union Member States; Patient Access Efforts Ongoing with Country-Specific Pricing and Reimbursement Processes news was largely expected, timeline is much faster than we anticipated, given that positive CHMP opinion was announced a month ago (sThe press release notes that RVMD is working to enable patient access in the EU, with timing dependent on country-specific pricing and reimbursement processes. believe RVMD has multiple clinical catalysts in the next 12 months, including daraxon+GnP update at the Triple Meeting this week
$RVMD #XBI #Biotechs - just one model - but worth looking into & probably owning few shares on pullback - might be LONGTIME if ever we see a LAUNCH like this in #BIOTECH over next few years
4
1
15
5,955
$NBIS CBO @romanchernin went on a podcast recently on The Compute 100 YT channel and dropped some bombshells👇 🟢1, They are truely GOING AFTER short term deals "Arkady told it today publicly (during GTC) we would love to have maybe half of all capacity, none less than half of all capacity we build available for such type of motion. Because we believe this is the best for us, this is the best yield per MW, this is the best business for us. And actually it's a good business for the customers because there is a lot of demand that quite spiky. You need to do a large training run, you know you'll need it for 3 months and you'd pay much higher price for 3 months if you can then go away and don't sit on this capacity for the next 5 years" 🟢2, $PLTR type of partnerships are coming "If someone would say me even six months ago we would have this partnership (the pltr) I wouldn't believe. I cannot say everything, but it's not last partnership of this type that is happening"
6
11
1
168
15,038
Pharmdca retweeted
Raymond James sticking with Strong Buy on $NVDA
8
36
3
296
16,584
TRUMP: SPOKE TO XI ABOUT CHIPS, AI LAST NIGHT MIGHT HAVE REFERRED TO NVIDIA SITUATION 'JUST BRIEFLY' COULD SELL BLACKWELLS IN 2, 3 YEARS HAVEN'T HEARD HUANG AFFAIR WAS NATIONAL SECURITY ISSUE
16
38
8
695
108,678
TRUMP: WE HAVE TO TAKE CARE OF PEOPLE LIKE JENSEN, ELON
21
92
12
1,717
76,137
Elon Musk says Nvidia made a mistake removing Jensen Huang, confirms he's spoken with him privately and says he would hire him himself: "who wouldn't?" "I would call Jensen, Michael Jordan, perhaps at his peak level, in terms of what he means to a team." "You got a winning streak that's just gonna happen, and then you kick Michael Jordan off your team. Doesn't seem like a smart decision to me." "There's no one that can really replace Jensen. He does the roles of several people. He's managing supply chain. He has long-term relationships that have been built up over decades. He understands his technology incredibly well." "His team loves him. And many of them are there because of him, and have had higher offers to go elsewhere and have turned them down because of personal loyalty to Jensen." "He's one of the most talented entrepreneur CEOs in history. Who wouldn't want to hire Jensen?"
322
1,225
111
9,084
644,696
Nice looking beat & raise for $PANW. Next-gen ARR & revenue ahead. Profit ahead. Q2 guidance ahead. Annual guidance raised. Every enterprise software investor feel free to say "thank you, Nikesh."
6
13
114
10,783
⚡ 𝗨𝗣𝗗𝗔𝗧𝗘: TEXAS RESUMES ISSUING 𝗗𝗔𝗧𝗔 𝗖𝗘𝗡𝗧𝗘𝗥 𝗔𝗜𝗥 𝗣𝗘𝗥𝗠𝗜𝗧𝗦 - $GOOGL $AMZN $NVDA $IREN $META Texas regulators said Wednesday they have resumed issuing air permits for data centers after last month’s pause. The state’s grid operator told regulators it had collected information on how proposed projects could affect local communities. The restart comes ahead of a January change in leadership. Gov.-elect Gina Hinojosa has pledged to impose a data center moratorium once she takes office. 👉 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 ➤ 𝗚𝗥𝗜𝗗 𝗖𝗢𝗡𝗡𝗘𝗖𝗧𝗜𝗢𝗡𝗦: In August, Gov. Greg Abbott halted new data center connections to the Texas electric grid and ordered an audit of proposed projects. He later temporarily blocked air permits for all data center projects. ➤ 𝗣𝗘𝗥𝗠𝗜𝗧 𝗥𝗘𝗩𝗜𝗘𝗪: Wednesday’s update concerns air permits. The Texas Commission on Environmental Quality (TCEQ) will review individual applications under applicable state and federal rules. ➤ 𝗝𝗔𝗡𝗨𝗔𝗥𝗬 𝗧𝗥𝗔𝗡𝗦𝗜𝗧𝗜𝗢𝗡: Hinojosa defeated Abbott in this month’s election. Her proposed moratorium would affect one of the world’s fastest-growing hubs for data center development. ➤ 𝗠𝗔𝗝𝗢𝗥 𝗢𝗣𝗘𝗥𝗔𝗧𝗢𝗥𝗦: Google, Microsoft, Meta and Amazon Web Services all have major data center operations in Texas. 👉 𝗘𝘅𝗽𝗲𝗿𝘁 𝗦𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀: 𝗟𝗮𝘂𝗿𝗮 𝗟𝗼𝗽𝗲𝘇, TCEQ spokesperson, said the agency resumed its normal review process after the grid operator notified it that it had gathered the community impact information for proposed projects.
1
15
1
71
11,297
$INTC CEO LIP-BU TAN ON AI DEMAND: "I JUST CANNOT SUPPLY ENOUGH." EXPECTS MORE AI CAPEX IN 2028 THAN 2027, THOUGH SPENDING MAY SHIFT AS FINANCING GETS HARDER "AGENTS ARE A LITTLE BIT LIKE TEENAGERS. THEY JUST GO AND DO THINGS." SAYS THE BUILD-OUT COULD SLOW A BIT AFTER THE MIDTERMS AND SOME CORRECTION IS HEALTHY, BUT OVERALL HE SEES NO SLOWDOWN
19
31
8
378
56,337